FDA Rejection Of Fosamax's Label Fix Not Final, 3rd Circ. Told
By P.J. D'Annunzio · March 5, 2024, 4:35 PM EST
Counsel for patients suing Merck over its osteoporosis drug Fosamax's alleged risk of causing painful bone fractures told a Third Circuit panel Tuesday that a Food and Drug Administration letter denying...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login